The purpose of this research article is to evaluate the impact of different types of PBS proton accelerators and spot sizes on interplay effects, mitigations, and plan quality for Stereotactic Body Radiation Therapy (SBRT) treatment of non-small cell lung cancer (NSCLC).

Dr Jonathan Farr DSc, Chief Clinical Officer of Advanced Oncotherapy plc, presents the results of a recent study undertaken with partners the Cleveland Clinic, which demonstrates the potential advantages of treating breast cancer with the LIGHT system, when compared to conventional cyclotrons. The study demonstrates that LIGHT proton minibeams could result in up to 99% reduction in radiation dose to critical organs, the heart and lungs, compared with cyclotron-generated protons.

On 26th September 2022 Advanced Oncotherapy reached a critical milestone in our journey in bringing a new linear accelerator proton treatment system to the market - the acceleration of the proton beam up to maximum system energy of 230 MeV.

Dr. Jonathan Farr, Chief Clinical Officer of Advanced Oncotherapy recently presented to the global medical physics and biomedical engineering community at IUPESM World Congress in Singapore. His presentation entitled “Ultra-High Dose Rate Production and Delivery Systems Intended for Flash”.

Dr. Jonathan Farr, Chief Clinical Officer of Advanced Oncotherapy interviewed with ProactiveInvestors to talk about the company's LIGHT, proton beam therapy system.

Nicolas Serandour, CEO of Advanced Oncotherapy is featured in the top 10 impactful healthcare leaders to watch in 2022. See his story on page 20 and his vision to democratise proton therapy.

Nicolas Serandour, CEO of Advanced Oncotherapy, interviewed with Proactive investors to discuss about democratising Proton Beam Therapy and provides an update on the development of the LIGHT system.

Advanced Oncotherapy plc reported new findings demonstrating the potential ability and superiority of its next-generation proton therapy system, LIGHT, to treat resistant cancers. The findings build on research at the Mayo Clinic that highlighted the benefits of combining proton therapy (PT) with targeted small molecule damage repair inhibitors.

The UK Investor Magazine Podcast was joined by Nicolas Serandour, CEO of Advanced Oncotherapy, to discuss the latest progress in democratising Proton Beam Therapy.

This study aims to investigate the use of proton Pencil Beam Scanning (PBS) for uniform FLASH irradiations in clinical and (radio)biology settings using a pulsed proton therapy Linac and to report on PBS FLASH beam delivery possibilities and limitations.

The purpose of the study is to determine which clinical indications benefit most and by how much from minimizing and holding a proton scanning spot size constant over the range 150-230 MeV in comparison to existing systems and techniques.

Advanced Oncotherapy held its Investor Day presentation on 19 October 2020. A recording of the presentation and of the full Q&A is available on the Investor Meet Company platform.

Advanced Oncotherapy (AIM:AVO), developer of proton therapy systems for cancer treatment, recently announced several areas of progress which will help realise its goal of ‘democratising proton therapy’.

Euan S. Thomson, PhD., Global President Ophthalmic Devices and Head of Digital Business Unit for Carl Zeiss Meditec, and Medical Advisor to Advanced Oncotherapy plc, shares his views on the future of data sharing for proton therapy and for Advanced Oncotherapy plc in particular. Treatment planning for proton therapy is complex and requires a number of steps to achieve the desired dose distributions. Without a national or international strategy to coordinate unified treatment protocols, patients treated with protons have been managed with several delivery modalities, treatment paradigms and fractionation schemes. A key area for optimising the treatment planning process is therefore in gaining experience by encouraging all centres to share treatment plans with each other, retrospectively and in real time. To facilitate this process, Advanced Oncotherapy is working on treatment planning software to be hosted on the cloud.

The combination of proton therapy with immunotherapy is considered promising and has gained substantial interest over the last 2 years. According to Prof Justin Stebbing, an internationally acclaimed expert in immunotherapies for cancer, “the synergies between immunotherapy and radiotherapy can potentially allow for better treatment of cancers, improving both quality and quantity of life.” A recent paper published in the British Journal of Radiology shows that proton therapy might be better adapted to for combination with immunotherapy because it causes less damage to the immune cells and induces a stronger immune response due to a different cell death mechanism.

FLASH continues to prove its unique advantages in healthy tissue sparing with tumour control even in radioresistant cases. The LIGHT system is uniquely suited to application of FLASH at all depths. Currently we are investigating the delivery FLASH dose rates for a wide range of spot sizes. Follow us at upcoming ASTRO for more details!

On page 83-85 of Healthcare in London magazine, CEO of Advanced Oncotherapy plc, Nicolas Serandour provides an update on the development of the LIGHT system.

Nicolas Serandour is CEO of Advanced Oncotherapy plc, a company not only at the forefront of developing a new proton beam therapy system, but also at the heart of a move to make this treatment available to people who would never normally have access to it.

The business and recent commercial agreements

On bringing proton beam therapy, a revolutionary new cancer treatment, to Harley Street

New data supporting the benefit of proton therapy is continuously emerging. See what Medpage says about proton therapy for paediatric brain tumours.

Advanced Oncotherapy plc is starting verification and validation of the world’s first linear proton beam accelerator system, which is assembled and ready for testing at the Daresbury particle physics laboratory in Cheshire, U.K.

Building work at 141-143 Harley Street, the site of Advanced Oncotherapy’s first proposed commercial installation of LIGHT, has been recently completed. The Company just announced handover ahead of the fit-out process. Below is a Q&A with Simon Baynham, the property director at The Howard de Walden Estate, the landlord and developer of the Harley Street Medical Area.

Because our LIGHT system has been designed to significantly reduce the treatment cost of patient and it can be installed in small to mid-size health care centres throughout the country, every patient ought to benefit from a proton therapy centre in their vicinity which is expected to drive patients’ demand for this treatment.

Check out the interview granted by Moataz Karmalawy, President of US division and Chief Commercial Officer of Advanced Oncotherapy.

Nicolas Serandour speaks to Sarah Neville about how LIGHT's streamlined design is going to help to bridge the gap between resources and demand, and “democratise” proton beam therapy, a treatment that can make a difference.

The news could scarcely have been better for Harry Muldowney, a 10-year-old Herefordshire schoolboy with a brain tumour. Last month he became one of the first NHS patients to begin a potentially life-saving course of proton beam therapy, a pioneering cancer treatment.

Prof Steve Myers, Executive Chair ADAM and former Director of Accelerators at CERN, was in Liverpool to talk about ‘Accelerating Innovation through International Collaboration’.

The front page of the Times features the story of how Caroline, a 9-year-old British girl diagnosed with a rare inoperable cancer known as a rhabdomyosarcoma, has made a full recovery thanks to proton beam therapy. Also available on StoryTrender

[Article in French] Listed on the London Stock Exchange, Advanced Oncotherapy believes it has discovered a real vein: the development of a new system focused on proton therapy. This promising technology fights cancer.

In October 2018, NHK World TV visited the ADAM bunker facility in Geneva and interviewed ADAM Chairman, Former CERN Director of Accelerators and Technology, Prof. Stephen Myers OBE.

This article in the Journal of Clinical Oncology provides strong support for the benefits of advanced radiation technologies such as proton therapy for the treatment of brain tumours, especially in younger patients.

AVO’s CEO Nicolas Serandour explains how the LIGHT system will significantly decrease the costs of proton therapy and allow to treat more kinds of cancer. “Proton therapy is going to become a reality for every cancer patient” - says Serandour

Physics World reports - Physics World reports on advances in proton therapy technology. Our LIGHT system is also discussed.

CERN Courier - "The first model of LIGHT, a linac-based hadron-therapy system that operates at [200 Hz] with an energy sweep, and which is going to be installed at Harley Street, London" was discussed at the first International Symposium on the Next Generation of Hadron Therapy in Tsukuba, Japan. See the article in the last edition of the CERN Courier.

Proton therapy is a new way of beating cancer, with fewer side effects than conventional radiation treatments, explains Stephen Myers a pioneering nuclear medicine scientist.

Carolyn Vachani (University of Pennsylvania) - OncoLink.com - This article compares various radiation oncology techniques.

Virginia Greco (CERN) - CERN Courier - The history of proton therapy.

BBC news

by Financial Times, Kate Burgess

Financial Times - Investors trust, that the LIGHT system is the future of proton therapy.

Thomas Bortfeld & Jay Loeffler (Mass. Gen. Hospital, Harvard Medical School) - Nature - Shrinking the accelerators and treatment room machines as well as model-based reimbursement decisions and pan-national referrals should decrease the cost of proton therapy and the scope of cancers treated.

A.C. Kraan, N. Depauw, B. Clasie, M. Giunta, T. Madden, Hanne M. Kooy - Medical Physics Volume 44, Issue 8 - Pencil-beam scanning in proton therapy is even more accurate than what would be medically necessary.

At its annual corporate event organised in Sardinia in 2017, Goetzpartners brought together personalities from all backgrounds. Prof Steve Myers, Executive Chairman of ADAM and Director of Advanced Oncotherapy plc, was invited to present the LIGHT Technology.

Following his appointment at Senior Independent Non-Executive Director, Hans von Celsing talks to DirectorsTalk about his past experience, the present and his thoughts on the future of the company.

A. Degiovanni, P. Stabile, D. Ungaro (A.D.A.M. SA) - NAPAC2016, Chicago, IL, USA - A detailed presentation of our proton therapy system.

The BMJ - Radiotherapy increases the probability of secondary malignancies in prostate cancer patients. Another argument for a more wide-spread use of proton therapy?

BBC News - Patient story about, how proton therapy is the better option in children's cancer.

Proton beam are not only useful in radiation therapy, but also as an imagining technique.

The Guardian - Thanks to proton therapy treatment the little Ashya King recovered very fast.

TMC news - A timeline of proton beam therapy development.

Wayne Newhauser & Rui Zhang - Physics in Medicine & Biology - Proton beam therapy explained by physicists.